

1 May 2019 12:00 BST

### **Transactions by Persons Discharging Managerial Responsibilities Disclosure under Article 19 of the EU Market Abuse Regulation**

AstraZeneca PLC (the Company) announces that, on 29 and 30 April 2019, it was notified of transactions in the Company's ordinary shares of \$0.25 each (Ordinary Shares) and American Depositary Shares (ADSs) by certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) as set out below. Two ADSs are equivalent to one Ordinary Share.

<b>PDMR</b>	<b>Position</b>	<b>Nature of the transaction</b>	<b>Quantity</b>	<b>Price</b>
Pascal Soriot	Chief Executive Officer	Purchase of Ordinary Shares	17,100	GB£58.255
Philip Broadley	Non-Executive Director	Purchase of Ordinary Shares	520	GB£57.38
Sheri McCoy	Non-Executive Director	Purchase of ADSs	2,372	US\$38.1783
Sheri McCoy	Non-Executive Director	Purchase of ADSs	100	US\$38.172
Deborah DiSanzo	Non-Executive Director	Purchase of ADSs	1,000	US\$38.3056

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Pascal Soriot
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	

a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares of US\$0.25 each in AstraZeneca PLC  GB0009895292					
b)	Nature of the transaction	Share purchase					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>GB£58.255</td><td>17,100</td></tr></table>		Price(s)	Volume(s)	GB£58.255	17,100
Price(s)	Volume(s)						
GB£58.255	17,100						
d)	Aggregated information  - Aggregated volume  - Price	Not applicable - single transaction					
e)	Date of the transaction	29 April 2019					
f)	Place of the transaction	XLON					

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Philip Broadley
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	

a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares of US\$0.25 each in AstraZeneca PLC  GB0009895292				
b)	Nature of the transaction	Share purchase				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>GB£57.38</td><td>520</td></tr></table>	Price(s)	Volume(s)	GB£57.38	520
Price(s)	Volume(s)					
GB£57.38	520					
d)	Aggregated information  - Aggregated volume  - Price	Not applicable - single transaction				
e)	Date of the transaction	30 April 2019				
f)	Place of the transaction	XLON				

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Sheri McCoy
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted								
a)	Description of the financial instrument, type of instrument  Identification code	AstraZeneca PLC American Depositary Shares  CUSIP: 046353108							
b)	Nature of the transaction	Purchase of AstraZeneca PLC American Depositary Shares							
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>US\$38.1783</td><td>2,372</td></tr><tr><td>US\$38.175</td><td>100</td></tr></table>		Price(s)	Volume(s)	US\$38.1783	2,372	US\$38.175	100
Price(s)	Volume(s)								
US\$38.1783	2,372								
US\$38.175	100								
d)	Aggregated information  - Aggregated volume  - Price	2,472  US\$38.178							
e)	Date of the transaction	29 April 2019							
f)	Place of the transaction	NYSE							

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Deborah DiSanzo
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	AstraZeneca PLC

b)	LEI	PY6ZZQWO2IZFZC3IOL08				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument  Identification code	AstraZeneca PLC American Depositary Shares  CUSIP: 046353108				
b)	Nature of the transaction	Purchase of AstraZeneca PLC American Depositary Shares				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>US\$38.3056</td><td>1,000</td></tr></table>	Price(s)	Volume(s)	US\$38.3056	1,000
Price(s)	Volume(s)					
US\$38.3056	1,000					
d)	Aggregated information  - Aggregated volume  - Price	Not applicable - single transaction				
e)	Date of the transaction	29 April 2019				
f)	Place of the transaction	NYSE				

#### About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit [astrazeneca.com](http://astrazeneca.com) and follow us on Twitter [@AstraZeneca](https://twitter.com/AstraZeneca).

#### Media Relations

Gonzalo Viña	UK/Global	+44 203 749 5916
Rob Skelding	UK/Global	+44 203 749 5821
Matt Kent	UK/Global	+44 203 749 5906
Jennifer Hursit	UK/Global	+44 203 749 5762

Christina M Hägerstrand	Sweden	+46 8 552 53 106
Michele Meixell	US	+1 302 885 2677

### **Investor Relations**

Thomas Kudsk Larsen		+44 203 749 5712
Henry Wheeler	Oncology	+44 203 749 5797
Christer Gruvris	BioPharma - Cardiovascular; Metabolism	+44 203 749 5711
Nick Stone	BioPharma - Respiratory; Renal	+44 203 749 5716
Josie Afolabi	Other	+44 203 749 5631
Craig Marks	Finance; Fixed Income	+44 7881 615 764
Jennifer Kretzmann	Retail Investors; Corporate Access	+44 203 749 5824
US toll-free		+1 866 381 72 77

**Adrian Kemp**  
**Company Secretary**  
**AstraZeneca PLC**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).